SlideShare a Scribd company logo
1 of 20
The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
References/Data Source ,[object Object],[object Object],[object Object],[object Object]
Table of Contents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Orphan Drug Act ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Provisions of the Orphan Drug Act: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Governmental Entities Implementing the Orphan Drug Act ,[object Object],[object Object],[object Object]
Has the Orphan Drug Act Met It’s Objectives? ,[object Object],[object Object],[object Object],[object Object]
Findings: ,[object Object],[object Object],[object Object],[object Object]
Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
Findings: ,[object Object],[object Object],[object Object],[object Object]
Conclusion: ,[object Object],[object Object],[object Object]
What Does This Mean To You?: Managed Care Vision Today & Beyond ,[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 
Regulatory requirement for europe union
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe unionShresthaPandey1
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agencyVicky Vignesh
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan DrugsANCY JOSE
 
Investigational new drug ,orange book,understanding on 505(b) (2) applications
Investigational new drug ,orange book,understanding  on  505(b) (2) applicationsInvestigational new drug ,orange book,understanding  on  505(b) (2) applications
Investigational new drug ,orange book,understanding on 505(b) (2) applicationsswrk
 
Clinical trial regulation in eu
Clinical trial regulation in euClinical trial regulation in eu
Clinical trial regulation in euKhushboo Bhatia
 
EudraVigilance DAS - Presentation
EudraVigilance DAS - PresentationEudraVigilance DAS - Presentation
EudraVigilance DAS - PresentationSalvatoreBI
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDr. Vishal Pawar
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countriesJAYA PRAKASH VELUCHURI
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and ndaswati2084
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
Hatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigationsHatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigationsAnumulaSurendra
 
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)RaghaviPillai
 
Therapeutic good administration
Therapeutic good administrationTherapeutic good administration
Therapeutic good administrationSagar Savale
 

What's hot (20)

Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union
 
Regulatory requirement for europe union
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe union
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agency
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
USFDA NDA Vs BLA
USFDA NDA Vs BLAUSFDA NDA Vs BLA
USFDA NDA Vs BLA
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Investigational new drug ,orange book,understanding on 505(b) (2) applications
Investigational new drug ,orange book,understanding  on  505(b) (2) applicationsInvestigational new drug ,orange book,understanding  on  505(b) (2) applications
Investigational new drug ,orange book,understanding on 505(b) (2) applications
 
Clinical trial regulation in eu
Clinical trial regulation in euClinical trial regulation in eu
Clinical trial regulation in eu
 
EudraVigilance DAS - Presentation
EudraVigilance DAS - PresentationEudraVigilance DAS - Presentation
EudraVigilance DAS - Presentation
 
Orphan drugs
Orphan drugsOrphan drugs
Orphan drugs
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan Drugs
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countries
 
Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
Hatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigationsHatch waxman act and paragraph iv litigations
Hatch waxman act and paragraph iv litigations
 
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
 
Therapeutic good administration
Therapeutic good administrationTherapeutic good administration
Therapeutic good administration
 

Similar to The Orphan Drug Act

The science of hope
The science of hopeThe science of hope
The science of hopeFreedom Monk
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesKuldeep Badoniya
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Harsha Rajasimha
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.docsuprajakotam
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigmsjalisman
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010HealthlinkWorldwide
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environmentspmaugeri
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...Dr Aneek Gupta
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...MedicineAndHealthUSA
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneAmerica's Health Insurance Plans
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2bahlinnm
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPMauro Placchi
 
RF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRichard Phillips
 

Similar to The Orphan Drug Act (20)

The science of hope
The science of hopeThe science of hope
The science of hope
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
 
MMHA 6135 WK 5 App
MMHA 6135 WK 5 AppMMHA 6135 WK 5 App
MMHA 6135 WK 5 App
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.doc
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharma
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigms
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010
 
Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environments
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMP
 
RF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology Assessment
 

The Orphan Drug Act

  • 1. The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.